期刊文献+

他克莫司药物浓度检测结果的多中心差异性研究 被引量:2

Multicenter study of methods and variations intacrolimus detection in China
原文传递
导出
摘要 目的综合分析多中心他克莫司血药浓度的检测数据差异,为改善检测方法和质控水平提供数据支持。方法本研究采用的低、中和高浓度他克莫司质控液产品在国际参考实验室的检测标准分别为(4.70±0.325)μg/L、(8.46±0.548)μg/L和(13.50±0.966)μg/L。将低、中、高浓度的他克莫司质控液样本通过冷链寄往全国34家器官移植中心,每次3个样本量,不同时间段重复完成2~3次寄送,共得到240个质控液样本的检测数据,对其进行统计学分析。结果本研究中,得到的低、中、高浓度组数据分别为(4.79±0.605)μg/L、(8.49±0.948)μg/L和(13.99±1.604)μg/L。相比之下,国外数据在低、中和高浓度3个水平的测试标准差和变异系数均较小。国际参考实验室对低、中、高3个浓度他克莫司质控液检测的标准差分别约为0.3、0.5和1.0,被本研究定义为"国际水准";而本次行业内调研数据的标准差分别约为0.5、1.0和1.5,暂被定义为"行业内水准"。结论建议拟定目前"行业内标准"即低、中和高浓度的他克莫司血药浓度检测误差允许范围分别为±0.5、±1.0和±1.5,要求每批次的检测样本中均应有1~2个"质控液",在使用新批次的"检测试剂"前必需用"标准液"重新定标,每个月均需用"标准液"重新定标并保持和临床医师的沟通。 Objective To improve the level of detection method and quality control at different transplant centers in China and comprehensively analyze the data of tacrolimus(Tac)detection in multiple transplant centers and provide data supports.Methods Low,medium and high concentration commercial quality control products in triplicate samples were delivered to 34 domestic organ transplantation centers and testing repeated for 2~3 times during different time periods.The detection results of 240 quality control samples were summarized.The methods,accuracy and stability of Tac detection results were analyzed.Results In international standard laboratories,mean±standard deviation(SD)of Tac detection results of low/medium/high concentration commercial quality control products was(4.70±0.325),(8.46±0.548)and(13.50±0.966)respectively.Here the results were(4.79±0.605),(8.49±0.948)and(13.99±1.604)respectively.In contrast,SD and degree of variation of international standard data were smaller,indicating that the accuracy and stability of international standard laboratories in detecting Tac were higher.SD of Tac concentrations detected by international standard laboratory for low/medium/high concentrations was approximately 0.3,0.5 and 1.0 respectively,i.e.International first-class level.Here SD was approximately 0.5,1.0 and 1.5 respectively,i.e.Chinese industry level.Conclusions The"Chinese industry level"is recommended.Before using a new batch of"testing reagents","standard control samples"must be employed for calibrating the calculated curve.The calculated curve should be re-calibrated at least once per month.And clinicians should be consulted frequently.
作者 陈松 谢林 兰培祥 陈知水 陈忠华 陈刚 Chen Song;Xie Lin;Lan Peixiang;Chen Zhishui;Chen Zhonghua;Chen Gang(Key Laboratory of organ transplantation,Tongji Hospital Affiliated to Tongji Medical College,Huazhong University of science and technology Key Laboratory of organ transplantation,Ministry of education Key Laboratory of organ transplantation,National Health Council Key Laboratory of organ transplantation,Chinese Academy of Medical Sciences,Wuhan 430032,China)
出处 《中华器官移植杂志》 CAS 2021年第3期147-152,共6页 Chinese Journal of Organ Transplantation
关键词 肾移植 他克莫司 血药浓度 Kidney transplantation Tacrolimus Blood drug level
  • 相关文献

参考文献3

二级参考文献39

  • 1焦正,杨洁,张明,施孝金.高效液相色谱法测定人血浆中咪唑立宾的浓度[J].中国新药与临床杂志,2006,25(7):489-491. 被引量:10
  • 2肖力,任斌,陈小陆.荧光偏振法测定去甲万古霉素血药浓度[J].齐齐哈尔医学院学报,2007,28(3):315-316. 被引量:9
  • 3Oellerich M, Hon, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments [ J ]. Ther Drug Monit, 2006,28(6) :720-725.
  • 4Khoschsorur G, Fruehwirth F, Zelzer S, et al. comparison of fluorescent polarization immunoassay ( FPIA ) versus HPLC to measure everolimus blood concentrations in clin- ical transplantation [ J ]. Clin Chim Acta, 2007,380 ( 1/ 2) :217-221.
  • 5Taylor PJ, Franklin ME, Graham KS, et al. A HPLC-mass spectrometric method suitable for the therapeutic drug mo- nitoring of everolimus [ J ]. J Chromatogr B, 2007,848 (2) :208-214.
  • 6Einecke G, Mai I, Fritsche L, et al. the value of C2 moni- toring in stable renal allograft recipients on maintenance immunosuppression [ J ]. Nephrol Dial Transplant, 2004, 19( 1 ) :215-222.
  • 7Umezawa Y, Ozawa A. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis [ J ]. Int J Dermato1,2007,46 ( 7 ) : 763-766.
  • 8Mathew BS, Fleming DH, Jeyaseelan V, et al. Alimited sampling strategy for tacrolimus in renal transplant pa- tients [ J ]. Br J Clin Pharmacol, 2008,66 (4) :467-472.
  • 9Crettol S, Venetz J-P, Fontana M ,et al.CYP3A7, CYP3A5, CYP'3A4 and ABCBlgenetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipi-ents [ J ]. Ther Drug Monit,2008,30 (6) :689-699.
  • 10Trevillian P. The CARI guidelines, calcineurin inhibitors in renal transplantation [ J ]. Nephrology, 2007,12 : S57-S65.

共引文献143

同被引文献5

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部